

**MAGEC2 Antibody**  
**Purified Rabbit Polyclonal Antibody (Pab)**  
**Catalog # AP51326****Specification**

---

**MAGEC2 Antibody - Product Information**

|                   |                        |
|-------------------|------------------------|
| Application       | WB, E                  |
| Primary Accession | <a href="#">Q9UBF1</a> |
| Reactivity        | Human, Mouse, Rat      |
| Host              | Rabbit                 |
| Clonality         | Polyclonal             |
| Calculated MW     | 41 KDa                 |

**MAGEC2 Antibody - Additional Information****Gene ID** 51438**Other Names**

Melanoma-associated antigen C2, Cancer/testis antigen 10, CT10, Hepatocellular carcinoma-associated antigen 587, MAGE-C2 antigen, MAGE-E1 antigen, MAGEC2, HCA587, MAGEE1

**Dilution**

WB~~1:1000

E~~N/A

**Format**

0.01M PBS, pH 7.2, 0.09% (W/V) Sodium azide, Glycerol 50%

**Storage**

Store at -20 °C. Stable for 12 months from date of receipt

**MAGEC2 Antibody - Protein Information****Name** MAGEC2**Synonyms** HCA587, MAGEE1**Function**

Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. In vitro enhances ubiquitin ligase activity of TRIM28 and stimulates p53/TP53 ubiquitination in presence of Ubl-conjugating enzyme UBE2H leading to p53/TP53 degradation. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzymes (E2) at the E3:substrate complex.

**Cellular Location**

Cytoplasm. Nucleus. Note=Nuclear in germ cells. Cytoplasmic in well-differentiated hepatocellular carcinoma, nuclear in moderately- and poorly-differentiated hepatocellular carcinoma

**Tissue Location**

Not expressed in normal tissues, except in germ cells in the seminiferous tubules and in Purkinje cells of the cerebellum. Expressed in various tumors, including melanoma, lymphoma, as well as pancreatic cancer, mammary gland cancer, non-small cell lung cancer and liver cancer. In hepatocellular carcinoma, there is an inverse correlation between tumor differentiation and protein expression, i.e. the lower the differentiation, the higher percentage of expression.

**MAGEC2 Antibody - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

**MAGEC2 Antibody - Images****MAGEC2 Antibody - Background**

Proposed to enhance ubiquitin ligase activity of RING- type zinc finger-containing E3 ubiquitin-protein ligases. In vitro enhances ubiquitin ligase activity of TRIM28 and stimulates p53/TP53 ubiquitination in presence of Ubl-conjugating enzyme UBE2H leading to p53/TP53 degradation. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzymes (E2) at the E3:substrate complex.

**MAGEC2 Antibody - References**

Gure A.O., et al. Int. J. Cancer 85:726-732(2000).  
Lucas S., et al. Int. J. Cancer 87:55-60(2000).  
Wang Y., et al. J. Immunol. 169:1102-1109(2002).  
Ross M.T., et al. Nature 434:325-337(2005).  
Li B., et al. Lab. Invest. 83:1185-1192(2003).